{
  "id": 11373312,
  "title": "Bereum Secures FDA, Journal, Patents",
  "url": "https://urgent.news/2026/10/02/bereum-secures-fda-journal-patents",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-02T06:28:53.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=278134"
  },
  "original_language": "en",
  "account": "Bereum Co., Ltd., a company specializing in postbiotics, has achieved significant milestones in its global healthcare market campaign. At the core of their success is the proprietary strain 'beLP1®' derived from kimchi. The company has successfully registered 'beLP1®' as a New Dietary Ingredient (NDI) with the United States Food and Drug Administration (FDA), marking a crucial step in ensuring the safety and regulatory compliance of their ingredient. This FDA approval not only guarantees the flawless safety of their product but also positions Bereum at the forefront of international standards.\n\nThe scientific backing for 'beLP1®' has been bolstered by a randomized, double-blind, placebo-controlled human study published in the prestigious 'Frontiers in Nutrition' journal. This study involved 140 overweight adults with a BMI of 25 to 35 kg/m² and demonstrated that consuming 'beLP1®' (over 30 billion cells) daily resulted in a significant decrease in gastrointestinal symptoms, particularly abdominal pain and indigestion, compared to a placebo group. Additionally, the study showed notable improvements in perceived stress levels and quality of life related to digestion. These results, highlighting the gut microbiome's beneficial bacteria increase and harmful pathogens decrease, underline the powerful gut health benefits of Bereum's technology.\n\nBuilding on their initial FDA NDI registration, Bereum has further solidified its technological prowess through the registration of core patents. These patents cover areas such as metabolic diseases and mental health, providing a strong legal monopoly for their differentiated postbiotics technology. Their ambition has been evident in securing these intellectual property protections, moving beyond the patent application stage to complete patent registrations for anti-stress compositions and obesity improvement compositions. This comprehensive approach to regulatory approval, scientific validation, and IP protection sets a robust foundation for Bereum to enter the global market and expand its influence across North America and beyond.",
  "summary": "Bereum Co., Ltd. (CEO Han Kwon-il), a company specializing in postbiotics, has fully kick-started its campaign to capture the global healthcare market, spearheaded by its kimchi-derived proprietary strain, ‘beLP1® (Lactiplantibacillus plantarum)’.Bereum recently completed the registration of ‘beLP1®",
  "key_points": [
    "Bereum's proprietary strain beLP1® registered as FDA New Dietary Ingredient.",
    "Double-blind study in Frontiers in Nutrition shows beLP1® reduces gastrointestinal symptoms.",
    "Bereum secures patents for anti-stress and obesity improvement compositions."
  ],
  "editors_take": "Bereum's FDA approval, journal publication, and patent registrations collectively signify a strong foundation for the company to assert its market leadership in postbiotics and expand globally with regulatory and intellectual property protection.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}